Drug has worked extremely well in myeloproliferative neoplasm called myelofibrosis of which there were about 18,000 known patients in the United States. It treats the very debilitating symptoms of the disease and also as part of that shrinks the very large spleens that many of these patients get. There is accumulating data that shows that the drug may well prolong survival, although we don’t have that in the label. And the drug was approved for use in intermediate and high-risk patients which comprise about 85% of that 18,000, and without any restriction on platelet count, despite the fact that we had only studied patients with platelet counts above 100,000 in our Phase III studies.
So the approval was towards the end of last year, and our revenue is growing in a steady and sustained way. And we are getting reports back from the field and from physicians that they are seeing pretty dramatic effects which is the same thing we saw in the Phase III studies.
I’m sure you don’t want to get more specific about some aspects of that, but in general that’s kind of the story.
David Friedman – Morgan Stanley & Co. LLCGreat. And so, maybe if we can just jump into the types of patients that have come on drug to date and it’s only been a couple of quarters. But if you can talk about just in the general sense the types of patients that you saw coming on drug in the first couple of months versus the contrast of the types of people you’ve seen come on drug in the past couple of months. Paul A. Friedman
Sure, but I think that is important to note. So the beauty of the label was we did not get a restriction for platelet count. The difficulty with the label that we’re dealing with aggressively is that without a limitation on platelet count, we saw in the beginning of our launch a very high proportion of the sicker patients who are too sick to get into our clinical trials that is patients with platelet counts less than 100,000. I mean over 60% of the patients who came in early in launch had platelet count in that range.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV